AI CuratorAI-generated

Research summary · 4 h ago

AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal

Pharmacovigilance Activities Related to Pregnancy and Breastfeeding in Multiple Sclerosis Drug Therapies

In a study involving 17 disease-modifying therapies (DMTs), researchers identified 21 pharmacovigilance activities concerning pregnancy and breastfeeding across 15 risk management plans. They found nine non-interventional cohort studies and four follow-up activities for pregnancy case studies, but three studies were terminated due to low recruitment rates.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42956735)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: Not reported
Evidence strength: Limited
Outcome: Not reported

Why it matters

This research highlights the need for enhanced surveillance of DMTs during pregnancy and breastfeeding, indicating possible gaps in safety data for these vulnerable populations.

What this does not prove

Data collection and recruitment of pregnant women presented significant challenges, leading to early termination of three studies for low recruitment.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 17 · basis not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: Not reported
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: Not reported
Size of effect: Not reported
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidenceSafety of Multiple Sclerosis Treatments During Pregnancy: An Overview of the EU Regulatory Approach to Risk Management Planning. ↗DOI: 10.1002/pds.70506

Supporting passages (6)

sample sizeRESULTS: We identified 17 DMTs that included 21 additional pharmacovigilance activities related to pregnancy and breastfeeding across 15 RMPs.

findingsRESULTS: We identified 17 DMTs that included 21 additional pharmacovigilance activities related to pregnancy and breastfeeding across 15 RMPs.

limitationsRecruiting pregnant women for studies is difficult, and three studies were stopped early for this reason.

peer reviewedPublication types: Journal Article

subjectsMeSH terms: Humans; Female; Pregnancy; Multiple Sclerosis; Pharmacovigilance; Breast Feeding; European Union; Risk Management; Pregnancy Complications; Cohort Studies; Adverse Drug Reaction Reporting Systems

study designMeSH terms: Humans; Female; Pregnancy; Multiple Sclerosis; Pharmacovigilance; Breast Feeding; European Union; Risk Management; Pregnancy Complications; Cohort Studies; Adverse Drug Reaction Reporting Systems

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.